Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Orenstein

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2015
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD StudyRobert Orenstein, Erik Dubberke, Robert Hardi, et al.
Mayo Clinic Proceedings|August 19, 2020
Research Response to SARS-CoV-2/COVID-19Charles D Burger, Amanda E Mikhail, Robert Orenstein, et al.
Inflammatory Bowel Diseases|January 25, 2025
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLSJessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, et al.
BMC Infectious Diseases|May 25, 2011
Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009Timothy C Olson, Tim Bongartz, Cynthia S Crowson, et al.
Infectious Diseases and Therapy|June 12, 2026
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical StudiesTeena Chopra, Daniel Van Handel, Brian Baggott, et al.
Open Forum Infectious Diseases|June 14, 2024
Deep Sternal Wound Infection Caused by <i>Rhizopus</i> Species After Coronary Artery Bypass GraftCody A Cunningham, Thomas E Grys, Francis X Downey, et al.
Therapeutic Advances in Gastroenterology|June 19, 2023
Safety of fecal microbiota, live-jslm (REBYOTA<sup>™</sup>) in individuals with recurrent <i>Clostridioides difficile</i> infection: data from five prospective clinical trialsChristine Lee, Thomas Louie, Lindy Bancke, et al.
The Journal of Infection|April 11, 2013
The impact of early and brief corticosteroids on the clinical course of primary pulmonary coccidioidomycosisNatalya Azadeh, Yu-Hui H Chang, Shimon Kusne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 3, 2017
Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile InfectionRoberto L Patron, Carlos A Hartmann, Sorcha Allen, et al.
Mycopathologia|August 6, 2016
Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical LiteratureColin Fitterer, Zachary Berg, Thorvardur R Halfdanarson, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2015
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD StudyRobert Orenstein, Erik Dubberke, Robert Hardi, et al.
Mayo Clinic Proceedings|August 19, 2020
Research Response to SARS-CoV-2/COVID-19Charles D Burger, Amanda E Mikhail, Robert Orenstein, et al.
Inflammatory Bowel Diseases|January 25, 2025
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLSJessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, et al.
BMC Infectious Diseases|May 25, 2011
Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009Timothy C Olson, Tim Bongartz, Cynthia S Crowson, et al.
Infectious Diseases and Therapy|June 12, 2026
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical StudiesTeena Chopra, Daniel Van Handel, Brian Baggott, et al.
Open Forum Infectious Diseases|June 14, 2024
Deep Sternal Wound Infection Caused by <i>Rhizopus</i> Species After Coronary Artery Bypass GraftCody A Cunningham, Thomas E Grys, Francis X Downey, et al.
Therapeutic Advances in Gastroenterology|June 19, 2023
Safety of fecal microbiota, live-jslm (REBYOTA<sup>™</sup>) in individuals with recurrent <i>Clostridioides difficile</i> infection: data from five prospective clinical trialsChristine Lee, Thomas Louie, Lindy Bancke, et al.
The Journal of Infection|April 11, 2013
The impact of early and brief corticosteroids on the clinical course of primary pulmonary coccidioidomycosisNatalya Azadeh, Yu-Hui H Chang, Shimon Kusne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 3, 2017
Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile InfectionRoberto L Patron, Carlos A Hartmann, Sorcha Allen, et al.
Mycopathologia|August 6, 2016
Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical LiteratureColin Fitterer, Zachary Berg, Thorvardur R Halfdanarson, et al.
Pageof 9